Intratumoral Hyperthermic Chemotherapy Injection in Peripheral Non-Small Cell Lung Cancer; Efficacy and Safety

faculty of medicine,Mansoura university0 个研究点目标入组 40 人开始时间: 2017年1月15日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•Patients with peripheral lung cancer planned to be treated by chemotherapy who include all of the following:
•1-Histologically-diagnosed, peripheral NSCLC.
•2-Patients who are not candidate for surgical treatment because of poor cardiopulmonary status, inoperable advanced stage of lung cancer or refusal of surgery
•3-The patients are fit for chemotherapy with adequate bone marrow reserve:
•¿White blood cell count >3500/mm3.
•¿Neutrophil count >1800/mm3.
•¿Hemoglobin >10 gm /dL.
•¿Haematocrit value >30%

•Patients with one or more of the following will be excluded:
•1.Patient is operable and planned for surgery.
•2.Tumors infiltrating the main stem bronchi, trachea and/or mediastinum as detected by fiberoptic bronchoscopy (FOB) and or CT chest (central bronchogenic carcinoma).
•3.Uncooperative patients.
•4.Patient with uncorrectable bleeding diathesis.
•5.Lung cancer other than NSCLC (small cell lung cancer, metastatic lung cancer, lymphoma, sarcoma, others ).
•6.Platelet count ¿ 50,000 mm3 and/or prothrombin time ¿ 50%.
•7.Serum bilirubin more than 2.5 mg/dL, ALT and AST > 3 times normal level and creatinine > 1.5 mg/dL.
•8.Patient with severe pulmonary dysfunction.
•9.Patient with uncompensated cardiac comorbidities.
•10. Hypersensitivity to cisplatin.

发起方